Literature DB >> 1719732

[Hydroxyethyl starch-induced transient renal failure in preexisting glomerular damage].

P Waldhausen1, H Kiesewetter, G Leipnitz, J Scielny, F Jung, R Bambauer, G von Blohn.   

Abstract

Hemorheological therapy through hemodilution has been gaining importance for several years and been applied to an ever increasing degree in stationary as well as in ambulant treatment. While renal insufficiency without previously established nephropathy is known to be a side effect of dextrans, cases of HES-induced nephropathy have so far not been reported. Two cases are presented in which in the course of stationary hemodilution therapy with HES an acute deterioration of an already exiting nephropathy was noted. Possible pathophysiological causes for such a deterioration are most likely to be found in an increased permeability of the glomerular basal lamina. Hydroxyethyl starch molecules are filtered above the physiological renal threshold which increases the viscosity of the primary urine. This can be counteracted by increasing diuresis. This conclusion can be drawn from our own observations which proved that renal insufficiency can be avoided through sufficient fluid intake (approx. 3 liters/day). In patients with creatinine values above 1.5/dl and arterial hypertension the indication for hemodilution therapy must be analysed carefully. If hemodilution therapy proves to be necessary, sufficient fluid intake must be guaranteed. Retention parameters must be controlled every other day in the course of the therapy. As an alternative, the administration of gelatin preparations should be considered as it does not cause cumulation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1719732

Source DB:  PubMed          Journal:  Acta Med Austriaca        ISSN: 0303-8173


  5 in total

1.  Hyperoncotic colloids in shock and risk of renal injury: enough evidence for a banning order?

Authors:  Patrick M Honore; Olivier Joannes-Boyau; Willem Boer
Journal:  Intensive Care Med       Date:  2008-08-07       Impact factor: 17.440

2.  Hydroxyethyl starch: the Paradigm of Eminence-Based Versus Evidence-Based Medicine-1.

Authors:  Federico Bilotta; Giovanni Giordano; Fabrizio Caroletti; Francesco Pugliese
Journal:  Turk J Anaesthesiol Reanim       Date:  2017-06-01

3.  Effects of a predominantly hydroxyethyl starch (HES)-based and a predominantly non HES-based fluid therapy on renal function in surgical ICU patients.

Authors:  Franziska Schabinski; Janaina Oishi; Fabio Tuche; Alain Luy; Yasser Sakr; Donald Bredle; Christiane Hartog; Konrad Reinhart
Journal:  Intensive Care Med       Date:  2009-06-17       Impact factor: 17.440

4.  Early fluid resuscitation with hyperoncotic hydroxyethyl starch 200/0.5 (10%) in severe burn injury.

Authors:  Markus Béchir; Milo A Puhan; Simona B Neff; Merlin Guggenheim; Volker Wedler; John F Stover; Reto Stocker; Thomas A Neff
Journal:  Crit Care       Date:  2010-06-28       Impact factor: 9.097

5.  Early fluid resuscitation with hydroxyethyl starch 130/0.4 (6%) in severe burn injury: a randomized, controlled, double-blind clinical trial.

Authors:  Markus Béchir; Milo A Puhan; Mario Fasshauer; Reto A Schuepbach; Reto Stocker; Thomas A Neff
Journal:  Crit Care       Date:  2013-12-23       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.